$224 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 13 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRTX | Buy | HERON THERAPEUTICS INC | $111,860,000 | +13.5% | 6,197,198 | +19.4% | 49.84% | +11.0% |
| LJPC | LA JOLLA PHARMACEUTICAL CO | $48,834,000 | -23.5% | 3,052,130 | 0.0% | 21.76% | -25.1% | |
| RXDX | Buy | IGNYTA INC | $21,533,000 | +7845.8% | 3,972,800 | +9832.0% | 9.59% | +7700.0% |
| OPKO HEALTH INCdebt 3.0% 2/1/33 | $19,753,000 | -9.5% | 14,000,000 | 0.0% | 8.80% | -11.5% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $7,019,000 | -5.7% | 90,215 | 0.0% | 3.13% | -7.7% | |
| BABA | ALIBABA GROUP HOLDING LIMITEDsponsored ads | $4,772,000 | +0.6% | 60,000 | 0.0% | 2.13% | -1.5% | |
| MERRIMACK PHARMACEUTICALS INCnote 4.5% 7/15/20 | $3,965,000 | -24.2% | 3,500,000 | 0.0% | 1.77% | -25.8% | ||
| NKTR | NEKTAR THERAPEUTICS | $3,700,000 | +3.5% | 260,000 | 0.0% | 1.65% | +1.3% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $1,221,000 | +0.3% | 430,000 | 0.0% | 0.54% | -1.8% | |
| LPCN | Buy | LIPOCINE INC | $790,000 | -22.2% | 260,000 | +160.0% | 0.35% | -23.8% |
| LIFE | Buy | ATYR PHARMA INC | $777,000 | +3.7% | 279,425 | +47.1% | 0.35% | +1.5% |
| CLDX | CELLDEX THERAPUETICS INC | $220,000 | +16.4% | 50,000 | 0.0% | 0.10% | +14.0% | |
| INFI | Exit | INFINITY PHARMACEUTICALS INC | $0 | – | -460,000 | -100.0% | -1.10% | – |
| OPK | Exit | OPKO HEALTH INC | $0 | – | -350,000 | -100.0% | -1.66% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -2.22% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.